HQP1351
- Generic Name
- HQP1351
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C29H27F3N6O
- CAS Number
- 1257628-77-5
- Unique Ingredient Identifier
- KV1M7Q3CBP
- Background
HQP1351 is under investigation in clinical trial NCT03883100 (A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation).
- Indication
用于治疗任何酪氨酸激酶抑制剂耐药，并采用经充分验证的检测方法诊断为伴有T315I突变的慢性髓细胞白血病慢性期或加速期的成年患者。
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Olverembatinib in the Treatment of Ph+ ALL
- Conditions
- Interventions
- First Posted Date
- 2022-07-20
- Last Posted Date
- 2022-09-01
- Lead Sponsor
- Chen Suning
- Target Recruit Count
- 55
- Registration Number
- NCT05466175
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, Jiangsu, China
Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs.
- Conditions
- Interventions
- First Posted Date
- 2022-04-05
- Last Posted Date
- 2022-07-29
- Lead Sponsor
- Shenzhen Second People's Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT05311943
- Locations
- 🇨🇳
Shenzhen Second People's Hospital, Shenzhen, Guangdong, China
A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase
- Conditions
- Interventions
- First Posted Date
- 2019-10-15
- Last Posted Date
- 2023-04-04
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 144
- Registration Number
- NCT04126681
- Locations
- 🇨🇳
Nanfang hospital of southern medical university, Guangzhou, Guangdong, China
🇨🇳Union Hospital medical college Huazhong University of Science and Technology, Wuhan, Hubei, China
🇨🇳The First Affiliated Hospital, Zhejiang University School of Medicine(hematology dept), Hangzhou, Zhejiang, China
Pharmacokinetics Profiles of HQP1351 Under Fasting and High-fat Meals in Patients With Chronic Myeloid Leukemia
- First Posted Date
- 2019-03-20
- Last Posted Date
- 2020-01-22
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT03882281
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation
- Conditions
- Interventions
- First Posted Date
- 2019-03-20
- Last Posted Date
- 2023-04-03
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT03883100
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guandong, China
🇨🇳Peking University People's Hospital, Beijing, Beijing, China
🇨🇳Shenzhen Second People's Hospital, Shenzhen, Guangdong, China
A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Chronic Phase With T315I Mutation
- Conditions
- Interventions
- First Posted Date
- 2019-03-20
- Last Posted Date
- 2023-04-03
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT03883087
- Locations
- 🇨🇳
Union Hospital medical college Huazhong University of Science and Technology, Wuhan, Hubei, China
🇨🇳Nanfang Hospital of Southern Medical University, Guanzhou, Guangdong, China
🇨🇳Peking University People's Hospital, Beijing, Beijing, China
A Study of HQP1351 in Patients With GIST or Other Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2018-07-20
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT03594422
- Locations
- 🇨🇳
Chinese PLA general hospital, Beijing, China, Beijing, China
🇨🇳Guangdong general hospital, Guangzhou, Guangdong, China
🇨🇳Henan cancer hospital, Zhengzhou, Henan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.